Related Experiment Video
Updated: Apr 7, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Using bioinformatic tools to identify high-risk variants of uncertain significance in aortopathy genes that increase
John DePaolo1, Dong-Chuan Guo2, David R Murdock2
1Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Purpose:
Variants of uncertain significance (VUS) represent are clinical challenging. We hypothesize that bioinformatic tools can identify VUS that are "high risk."
Methods:
Primary analyses were performed in the Penn Medicine Biobank, which is composed of 43,731 participants, 11,925 of whom carried at least 1 missense VUS in the 11 genes associated with heritable thoracic aortic disease. VUS rare exome variant ensemble learner, AlphaMissense, and minor allele frequency high-risk thresholds were derived using cutpointR. These cutpoints were used to test the association of high-risk VUS with prevalent thoracic aortic disease.
Results:
In the Penn Medicine Biobank, being heterozygous for a VUS was associated with a modest increased risk of thoracic aortic aneurysm (TAA: OR = 1.14, 95% confidence interval [CI] 1.01 to 1.29, P = .034) but no increased risk of aortic dissection (OR = 1.04, 95% CI 0.55 to 2.00, P = .896). Using cutpointR, we derived are exome variant ensemble learner (>0.649), AlphaMissense (>0.2543), and minor allele frequency (<8.16 × 10-6) cutpoints that identified 435 high-risk VUS that were robustly associated with prevalent dissection (OR = 7.85, 95% CI 4.73 to 13.03, P < .001), although the association with TAA was attenuated (OR = 2.35, 95% CI 1.62 to 3.42, P < .001). Similar results were observed in 2 independent validation cohorts.
Conclusion:
High-risk VUS were strongly associated with aortic dissection, suggesting that high-risk thresholds may be applied clinically.
More Related Videos
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Aortic Regurgitation II: Clinical Features and Diagnostic Tests

